Gilead Limits Enrollment in Its Hep C Patient Program to Pressure Insurers

July 16, 2015

The Wall Street Journal’s Pharmalot Blog (Silverman, 7/16) reported that “Gilead Sciences is limiting enrollment to its patient assistance program for hepatitis C drugs.” This is being done in response to some payers restricting access to its hepatitis C medicines. Gilead believes that limiting enrollment will result in patients putting pressure on payers regarding lack of access. “Nonetheless, payers are free to place restrictions on the drugs, thus lowering their own costs. So while some payers have since provided coverage for the Gilead drugs without restrictions, others still maintain restrictions.”